{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_5",
        "affectedSection": "Schedules of Activities and Section 6",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Implementation of C-SSRS administration across all ongoing subjects and multiple study phases."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_5",
        "affectedSection": "Secondary Objectives",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Removal of specific patient-reported outcome (PRO) endpoints to align with the SAP."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_5",
        "affectedSection": "Sections 1, 2, 5, 6, 7 and Appendix 3",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Various administrative changes regarding dosing timing, PK sampling, and washout periods."
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_4",
        "affectedSection": "Schedule of Activities, Sections 4, 6, and 7",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Implementation of Hepatitis B monitoring risk protocols for Taiwan."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_5",
        "reasonText": "To align with new cross-program processes for suicide severity rating.",
        "category": "Safety",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_5",
        "reasonText": "To align secondary objectives with the Statistical Analysis Plan.",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_4",
        "reasonText": "High prevalence of specific Hepatitis B serology in Taiwan requiring risk monitoring.",
        "category": "Safety",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "amend_3",
        "reasonText": "Requested by an Ethics Committee in China for study B7451013.",
        "category": "Regulatory",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_5",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "6",
        "afterText": "C-SSRS will be administered to all ongoing subjects at all remaining scheduled visits in Run In and Blinded treatments, and Rescue weeks 0, 8, 12, 16, and up to and including EOT/ET and/or EOS.",
        "summary": "Added Columbia Suicide Severity Rating Scale (C-SSRS) monitoring."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_5",
        "changeType": "Deletion",
        "instanceType": "StudyChange",
        "sectionNumber": "Secondary Objectives",
        "beforeText": "EQ-5D-5L / EQ-5D-Y, FACIT-F/Peds-FACIT-F, and SF-36",
        "summary": "Removal of specific PRO endpoints from secondary objectives."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_5",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "Appendix 3",
        "beforeText": "Previous washout period for CYP2C9 and CYP2C19 inducers",
        "afterText": "Updated washout period for CYP2C9 and CYP2C19 inducers",
        "summary": "Update and clarification of washout periods for specific enzyme inducers."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_3",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "Screening",
        "afterText": "Subjects who are HBsAg negative, HBcAb positive, and HBsAb positive at Screening will have reflex testing for HBV DNA.",
        "summary": "Added reflex HBV DNA testing for specific Hepatitis B serology profiles in China."
      }
    ],
    "summary": {
      "impactCount": 4,
      "reasonCount": 4,
      "changeCount": 4
    }
  }
}